Patients with non-ACS, who planned to undergo elective PCI for de novo coronary lesions, were admitted to the Cardiac Center of Shanghai Chest Hospital affiliated to Shanghai Jiao Tong University from May 2019 to May 2020. Among them, those with single-vessel disease and thrombolysis in myocardial infarction (TIMI) grade 3 following PCI were included in this study. Exclusion criteria were as follows: i) contraindication of intracoronary nicorandil or alprostadil administration; ii) elevated cardiac troponin I (cTnI) at baseline; iii) left main disease or bifurcation lesion requiring side-branch intervention or chronic total occlusion; iv) history of myocardial infarction or coronary artery bypass grafting; v) pregnancy; and vi) other complications, including cardiac shock, severe arrhythmia, end-stage renal disease, or other comorbidities with prognoses of less than 12 months.

The study was approved by the ethical committee of Shanghai Chest Hospital. Written informed consent was obtained from all the study participants. All procedures were conducted according to the principles laid down in the World Medical Association's Declaration of Helsinki. The study was registered at www.clinicaltrials.gov (unique identifier: NCT03252665).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.